The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
 
Evan Y. Yu
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Incyte; Janssen; Merck; Pharmacyclics; QED Therapeutics; Seagen
Research Funding - Daiichi Sankyo (Inst); Dendreon (Inst); Merck (Inst); Seagen (Inst); Taicho (Inst)
 
Josep M. Piulats
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Clovis Oncology; Janssen Oncology; Merck Sharp & Dohme; Roche/Genentech; VCN Biosciences
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Incyte; Janssen Oncology; Merck Sharp & Dohme; Pfizer/EMD Serono
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen Oncology; Roche
 
Gwenaelle Gravis
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Pfizer; Sanofi
 
Brigitte Laguerre
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen-Cilag; Roche; Sanofi
Travel, Accommodations, Expenses - Astellas Pharma; Janssen Oncology; Novartis; pfizer
 
Jose Angel Arranz Arija
Honoraria - Astellas Pharma; Bristol-Myers Squibb; EUSA Pharma; Janssen-Cilag; MSD Oncology; Novartis
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; EUSA Pharma; Ipsen; Janssen-Cilag; MSD Oncology; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Pierre Fabre (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen-Cilag; MSD Oncology; Pfizer
 
Stephane Oudard
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; IPSEN; Janssen; Merck; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; IPSEN; Janssen; Merck; MSD Oncology; MSD Oncology; Novartis; Pfizer; Roche; Roche; Sanofi
Research Funding - Ipsen; Sanofi
Travel, Accommodations, Expenses - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Merck; MSD Oncology; Novartis; Pfizer; Roche
 
Peter C.C. Fong
Honoraria - AstraZeneca; MSD
Consulting or Advisory Role - MSD
Speakers' Bureau - Janssen
Travel, Accommodations, Expenses - Pfizer
 
Michael Paul Kolinsky
Honoraria - Janssen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; Merck
 
Marinela Augustin
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Lilly; Novartis; Pfizer; PharmaMar; Roche
Travel, Accommodations, Expenses - Ipsen; Novartis; PharmaMar
 
Susan Feyerabend
No Relationships to Disclose
 
Audrey E. Kam
No Relationships to Disclose
 
Howard Gurney
Honoraria - Pfizer
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Janssen-Cilag (Inst); Merck Sharp & Dohme (Inst)
Speakers' Bureau - AstraZeneca; AstraZeneca
Travel, Accommodations, Expenses - Astellas Pharma
 
Ali Tafreshi
No Relationships to Disclose
 
Margitta Retz
No Relationships to Disclose
 
William R. Berry
Honoraria - Bayer
Consulting or Advisory Role - Merck
Speakers' Bureau - Bayer
Research Funding - Merck
Travel, Accommodations, Expenses - Bayer; Merck
 
Nataliya Mar
No Relationships to Disclose
 
Helen Wu
Employment - MSD
Stock and Other Ownership Interests - Merck Sharp & Dohme (I)
Travel, Accommodations, Expenses - MSD RD China
 
Charles Schloss
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Christian Heinrich Poehlein
Employment - Merck
Leadership - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Johann S. De Bono
Honoraria - Astellas Pharma; AstraZeneca; BioExcel; Daiichi Sankyo; Genentech/Roche; Janssen Oncology; Menarini Silicon Biosystems; Pfizer; Sanofi; Sierra Oncology
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; Celgene; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Janssen Oncology; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi; Sierra Oncology; Taiho Pharmaceutical
Research Funding - Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); CellCentric (Inst); Daiichi Sankyo (Inst); Genentech (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Medivation (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Orion (Inst); Sanofi (Inst); Sierra Oncology (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Genmab; GlaxoSmithKline; Orion; Qiagen; Sanofi; Taiho Pharmaceutical; Vertex